Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $52620.0.

  • BioRestorative Therapies' Depreciation & Amortization (CF) rose 901.41% to $52620.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $207518.0, marking a year-over-year increase of 1439.8%. This contributed to the annual value of $189056.0 for FY2024, which is 1407.13% up from last year.
  • According to the latest figures from Q3 2025, BioRestorative Therapies' Depreciation & Amortization (CF) is $52620.0, which was up 901.41% from $52748.0 recorded in Q2 2025.
  • Over the past 5 years, BioRestorative Therapies' Depreciation & Amortization (CF) peaked at $52748.0 during Q2 2025, and registered a low of $21496.0 during Q4 2021.
  • Over the past 5 years, BioRestorative Therapies' median Depreciation & Amortization (CF) value was $41526.0 (recorded in 2023), while the average stood at $37978.6.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first crashed by 4470.11% in 2021, then skyrocketed by 5128.6% in 2023.
  • BioRestorative Therapies' Depreciation & Amortization (CF) (Quarter) stood at $21496.0 in 2021, then skyrocketed by 47.91% to $31794.0 in 2022, then soared by 34.34% to $42713.0 in 2023, then grew by 17.92% to $50369.0 in 2024, then increased by 4.47% to $52620.0 in 2025.
  • Its Depreciation & Amortization (CF) was $52620.0 in Q3 2025, compared to $52748.0 in Q2 2025 and $51781.0 in Q1 2025.